Evidence map›Paper›PMID 28560665›Full record

ReviewJournal of neuro-oncology2017

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Charles A Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian Shi, Lewis C Strauss, C Norman Coleman, Mansoor M Ahmed

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. An End-to-endProceedings. IEEE International Conference on Healthcare Informatics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charles A KunosInvestigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Evanthia GalanisMayo Clinic Cancer Center, Mayo Clinic, Rochester, MN, USA.
Jeffrey BuchsbaumRadiation Research Program, National Cancer Institute, Bethesda, MD, USA.
Qian ShiMayo Clinic Cancer Center, Mayo Clinic, Rochester, MN, USA.
Lewis C StraussBristol-Myers Squibb, Lawrenceville, NJ, USA.
C Norman ColemanRadiation Research Program, National Cancer Institute, Bethesda, MD, USA.
Mansoor M AhmedRadiation Research Program, National Cancer Institute, Bethesda, MD, USA. mansoor.ahmed@nih.gov.

Funding

Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomasR01CA154348 · NCI · MAYO CLINIC ROCHESTER · PI GALANIS, EVANTHIA · 2011 to 2014
$1.3M
Intramural NIH HHS Z99 CA999999NCI NIH HHS P50CA10896NCI NIH HHS R01 CA154348NCI NIH HHS R01CA154348
6 · The paper itself

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation-chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation-investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Indexed as

ChemoradiotherapyAntineoplastic AgentsBiomarkers, TumorBrain NeoplasmsClinical Trials as TopicDrug DiscoveryGlioblastomaHumansAntineoplastic AgentsBiomarkers, TumorCancer discoveryClinical cancer researchClinical trialsExperimental chemotherapyPrecision medicineRadiotherapy

Identifiers

PMID28560665
PMCPMC5709276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.